Regeneron UK

Regeneron gene therapy hearing loss pivot

FDA · hearing loss · 4 min

Sensorion has redirected its hearing-loss strategy after Regeneron’s Otarmeni became the first and only FDA-approved in vivo gene therapy for OTOF-related hearing loss. The move underscores a widening split between rare OTOF programs and broader GJB2-targeted opportunities.

When was Dupixent approved for COPD?

FDA · chronic obstructive pulmonary disease · 6 min

The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.

Regeneron Pharma Stock Holds Steady Amid EMA Eye Drug Review and Analyst Target Adjustment

EMA · eye drug · 6 min

Regeneron Pharmaceuticals' stock shows resilience despite a recent analyst price target reduction and ongoing European Medicines Agency (EMA) review of an eye drug. The market appears to be absorbing these developments without significant share price volatility.

Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights

2 min

Regeneron Pharma stock is in the spotlight following significant institutional buying. This article explores the implications for investors and pharma teams.